10:11:51 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-08-29 Bokslutskommuniké 2023
2023-05-25 Kvartalsrapport 2023-Q3
2023-05-17 Extra Bolagsstämma 2023
2023-02-23 Kvartalsrapport 2023-Q2
2022-11-24 Ordinarie utdelning SELECT B 0.00 SEK
2022-11-23 Årsstämma 2023
2022-11-16 Kvartalsrapport 2023-Q1
2022-08-30 Bokslutskommuniké 2022
2022-05-24 Kvartalsrapport 2022-Q3
2022-02-24 Kvartalsrapport 2022-Q2
2021-11-25 Ordinarie utdelning SELECT B 0.00 SEK
2021-11-24 Årsstämma 2022
2021-11-18 Kvartalsrapport 2022-Q1
2021-08-31 Bokslutskommuniké 2021
2021-05-25 Kvartalsrapport 2021-Q3
2021-02-26 Kvartalsrapport 2021-Q2
2020-11-27 Kvartalsrapport 2021-Q1
2020-11-26 Årsstämma 2021
2020-11-26 Ordinarie utdelning SELECT B 0.00 SEK
2020-08-27 Bokslutskommuniké 2020
2020-05-20 Kvartalsrapport 2020-Q3
2020-02-20 Kvartalsrapport 2020-Q2
2019-11-21 Ordinarie utdelning SELECT B 0.00 SEK
2019-11-20 Årsstämma 2020
2019-11-07 Kvartalsrapport 2020-Q1
2019-08-29 Bokslutskommuniké 2019


IndustriLäkemedel & Handel
SelectImmune Pharma är ett läkemedelsbolag. Bolaget ämnar utveckla läkemedelskandidater med fokus på endogena inflammatoriska medel och bakteriemolekyler. Produkterna är inriktade mot att förstärka immunsystemet och används huvudsakligen för behandling av infektionssjukdomar, samt kronisk inflammation. Bolaget grundades år 2017 och innehar störst verksamhet inom den nordiska marknaden.
2021-08-19 15:30:00

The successful outcome of a new treatment approach is now reported for patients with severe bladder pain. The publication presents data showing that an IL-1 receptor antagonist (IL-1RA) reduces pain and increases the quality of life in this severely handicapped patient group. Preliminary findings were reported in 2020.

The results are published in European Urology Open Science, a leading journal in the field of urology that publishes international discoveries with clinical relevance (Wullt et al. 2021. Immunomodulation - A Molecular Solution to Treating Patients with Severe Bladder Pain Syndrome? Eur. Urol. Open Sci. 31, 49-58; doi: 10.1016/j.euros.2021.07.003 (https://doi.org/10.1016/j.euros.2021.07.003)). SelectImmune Pharma is developing this new treatment approach for bladder pain as well as recurrent cystitis.

Patients with bladder pain syndrome experience debilitating pain and extreme frequency of urination. Numerous therapeutic approaches have been tested but as the molecular basis of disease has remained unclear, specific therapies have not been available. Scientists at Lund University have shown that the pain response in the bladder is accentuated by interleukin 1 (IL-1) and that treatment with an IL-1 receptor antagonist (IL-1RA) restores bladder health in susceptible mice, linking IL-1-dependent inflammation to pain and bladder pathology.

IL-1RA treatment is now proposed to be beneficial in patients with severe bladder pain syndrome. Treatment reduced bladder pain and increased the quality of life in 13 out of 17 patients, and responders returned to a more normal lifestyle. At the molecular level, treatment inhibited destructive neuro-inflammation and pain sensing was lowered. Neuro-inflammatory- and IL-1-dependent gene networks were inhibited.

The potent acute effect and lasting symptom relief in responding patients indicate that this therapeutic approach is worth exploring in controlled clinical trials.

"We are proud to have taken our molecular discoveries all the way to the clinic," says Ines Ambite, research scientist at Lund University and R&D coordinator, SelectImmune Pharma.

"The clinical findings confirm the potential of IL1-RA therapy in bladder pain and cystitis," says Björn Wullt, urologist and physician responsible for the treatment and follow up.   


For more information, please contact:

Catharina Svanborg

Chairman of the board SelectImmune Pharma AB

Phone: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

Ann Gidner

CEO SelectImmune Pharma AB

Phone: +46 768 17 14 14

E-mail: ann.gidner@selectImmune.com